Rafferty Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Rafferty Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-79,622	Closed	-$2.67M	–	1161
2026 Q1	$2.67M	Sell	79,622 -15,975	-17%	-$626K	0.01%	548
2025 Q4	$4.43M	Buy	95,597 +3,122	+3%	+$171K	0.02%	457
2025 Q3	$6.25M	Buy	92,475 +45,076	+95%	+$3.34M	0.02%	378
2025 Q2	$3.97M	Buy	47,399 +1,046	+2%	+$78.3K	0.01%	444
2025 Q1	$3.31M	Sell	46,353 -20,127	-30%	-$980K	0.01%	455
2024 Q4	$2.99M	Buy	66,480 +9,847	+17%	+$510K	0.01%	526
2024 Q3	$2.86M	Buy	56,633 +2,696	+5%	+$129K	0.01%	549
2024 Q2	$2.2M	Sell	53,937 -52,207	-49%	-$2.21M	0.01%	617
2024 Q1	$4.54M	Buy	106,144 +54,270	+105%	+$2.45M	0.02%	492
2023 Q4	$2.09M	Buy	+51,874	New	+$1.48M	0.01%	665

Rafferty Asset Management's SLNO Position: Q2 2026 in Review

Rafferty Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 79,622 shares — an estimated $2.67M sold.

Rafferty Asset Management first reported a position in SLNO in Q4 2023 and held it in 10 quarters. The position peaked at $6.25M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Rafferty Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Rafferty Asset Management sold 79,622 Soleno Therapeutics shares in Q2 2026, an estimated $2.67M.
Rafferty Asset Management first reported a position in Soleno Therapeutics in Q4 2023 and held it in 10 quarters.
Rafferty Asset Management's Soleno Therapeutics position peaked at $6.25M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.